Eden Research plc
LSE : EDE

May 21, 2009 04:23 ET

Director Shareholding

Eden Research plc
Grant of Options

On  19  May  2009  the Board of Eden Research plc ("Eden") granted options to the following  directors
under the terms of its Share Option Scheme:

Director                                Share options granted             Total options held

Ken Brooks                                            900,000                      2,878,487
Timothy Griffiths                                     900,000                      2,878,487
Alex Abrey                                            450,000                        550,000
Clive Newitt                                          150,000                        225,000
Stephen O'Brien                                       100,000                        100,000
Sir Ben Gill                                          100,000                        100,000

The new options can be exercised at a price of 26 pence per share and have been granted in recognition
of  the directors' efforts over the past three years to bring Eden towards commercialisation and as  a
result  of the Company's low remuneration policy. The options can be exercised any time up to  19  May
2014.

For further information:
Tim Griffiths, Chief Executive             Eden Research plc     Tel: 01993 868844

Matthew Robinson                           FinnCap               Tel: 020 7600 1658


ABOUT EDEN RESEARCH PLC

Eden  Research plc is a UK publicly listed company on the PLUS Market, specialising in the development
of agrochemical products and intellectual property through licensing  and  marketing agreements.

Eden  is focused on developing products for the agricultural sector through the application of terpene
chemistry  and  other  patented  environmentally friendly technologies.   Eden  is  currently  working
alongside   universities   and  partner  companies  in  developing  its  product   portfolio   towards
commercialisation.

For further information please visit www.edenresearch.com.

Contact Information

  • Eden Research plc